Skip to content

Pulsar-18 T3 6/30/90Recalls & reported problems

Biotronik AG · Class 3 · Implant

All models of Pulsar-18 T3 (52)

Data updated Oct 18, 2026 from official FDA records · Editorial policy

Adverse event reports
1
Deaths reported
0
Injuries reported
0
Recalls naming it
0

Summary

The FDA's MAUDE database contains 1 adverse event report that list this exact device (DI 07640130446564), received between Nov 30, 2022 and Nov 30, 2022 — classified as 1 malfunction.

The most frequently reported specific device problem is “Malposition of Device” (1 report).

Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 18, 2026.

Most reported problems

Device problems

  • Malposition of Device1

Patient problems

  • No Clinical Signs, Symptoms or Conditions1

Recent adverse event reports

The 1 most recent of 1 reports, in the reporter's own words as published by the FDA.

  • MalfunctionNov 30, 2022Malposition of Device; Malposition of Device

    A PULSAR-18 T3 SELF-EXPANDABLE STENT SYSTEM WAS SELECTED FOR TREATMENT OF A SMALL FOCAL STENOSIS IN THE LEFT MID COMMON FEMORAL ARTERY PROXIMAL TO A BYPASS GRAFT. THE PULSAR-18 T3 CROSSED THE LESION WITHOUT ISSUE. DURING DEPLOYMENT, THE STENT JUMPED OUT OF THE SHAFT AND MIGRATED DISTALLY TO THE TARGET LESION. THEN A LONGER PTX STENT WAS PLACED THROUGH THE PULSAR-18 T3 STENT FOR JAILING AND SECURING IT. THE DELIVERY SYSTEM WAS CONFIRMED TO BE LESS THAN 25 PERCENT DEPLOYED UNDER FLUOROSCOPY.

    Patient problems: No Clinical Signs, Symptoms or Conditions

    MAUDE report 15887647 ↗

Other STENT, SUPERFICIAL FEMORAL ARTERY devices

All STENT, SUPERFICIAL FEMORAL ARTERY devices →

Sources and updates

How reports and recalls are matched · Editorial policy · Report an error on this page